Biology and treatment of Burkitt's lymphoma

@article{Yustein2007BiologyAT,
  title={Biology and treatment of Burkitt's lymphoma},
  author={Jason T. Yustein and Chi Van Dang},
  journal={Current Opinion in Hematology},
  year={2007},
  volume={14},
  pages={375–381}
}
  • J. Yustein, C. Dang
  • Published 1 July 2007
  • Medicine, Biology
  • Current Opinion in Hematology
Purpose of reviewBurkitt's lymphoma is a unique hematological malignancy remarkable for its biological characteristics, including aberrant expression of the MYC oncogene, and its requirement for intensive treatment regimens. This review will focus on those features, and discuss recent advances in the molecular biology and advancing treatment options for the disease. Recent findingsAdvances in molecular biology have provided many new insights into the biology and treatment options for Burkitt's… 
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
TLDR
High-throughput RNA sequencing and RNA interference screening is used to discover essential regulatory pathways in Burkitt's lymphoma that cooperate with MYC, the defining oncogene of this cancer.
Signaling Pathways in Rare Lymphomas
Here we give an overview of select signaling pathways understood or thought to play a key role in the pathogenesis of lymphomas, covering examples of both B-cell and T-cell lymphomas. The selection
Identification and functional characterisation of oncogenic pathway signatures in malignant lymphoma
TLDR
New gene expression patterns holding information about B cell relevant oncogenic pathways were identified and can be used to infer on the activity of deregulated pathways in malignant lymphoma based on their gene expression profiles.
Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments.
TLDR
Advances in understanding of the pathobiology of EBV oncogenesis, including the transforming and immunogenic properties of the virus and the role of immune dysregulation, have provided the rationale for new treatment strategies.
Burkitt's lymphoma in a young Brazilian boy.
TLDR
A case of oral Burkitt's lymphoma involving the right jaw in a 4-year-old boy with rapidly-enlarging swelling of one month duration, toothache-like pain and radiographical appearance of 'floating teeth' in the right mandible is described.
Signaling pathways in lymphoma: pathogenesis and therapeutic
TLDR
It is proposed that the entry into a kinase inhibitor era of lymphoma therapy will be as transformative for patients as the advent of the antibody or chemotherapy era before it.
Burkitt Lymphoma: Pathogenesis and Immune Evasion
TLDR
An overview of Burkitt lymphoma and its association with EBV and the c-myc oncogene is provided, and recent developments suggesting the existence of BL-associated inhibitory molecules that may block HLA class II-mediated Ag presentation to CD4+ T cells, facilitating immune escape of BL are provided.
Signaling pathways in lymphoma: pathogenesis and therapeutic targets.
TLDR
It is proposed that the entry into a kinase inhibitor era of lymphoma therapy will be as transformative for patients as the advent of the antibody or chemotherapy era before it.
E2F1 expression is deregulated and plays an oncogenic role in sporadic Burkitt's lymphoma.
TLDR
It is found that E2F1 is highly expressed in Burkitt's lymphoma cell lines and sBL lymphoma specimens and shown that reduction of its expression in sBL cells inhibits tumor formation and decreases their proliferation rate.
Burkitt's lymphoma in a young Brazilian boy.
TLDR
A case of oral Burkitt’s lymphoma involving the right jaw in a 4-year-old boy with rapidly-enlarging swelling of one month duration, toothache-like pain and radiographical appearance of ‘fl oating teeth’ in the right mandible is described.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 70 REFERENCES
Molecular diagnosis of Burkitt's lymphoma.
TLDR
Gene-expression profiling is an accurate, quantitative method for distinguishing Burkitt's lymphoma from diffuse large-B-cell lymphoma and the overall survival was superior among those who had received intensive chemotherapy regimens instead of lower-dose regimens.
A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.
TLDR
The molecular definition of Burkitt's lymphoma clarifies and extends the spectrum of the WHO criteria for Burkitt’s lymphoma.
Burkitt's lymphoma: clinicopathologic features and differential diagnosis.
TLDR
With the publication of the WHO Classification of Haematopoietic and Lymphoid Tumors, the nomenclature of this lymphoma has come full circle, and it is once again known simply as Burkitt's lymphoma.
Adult Burkitt leukemia and lymphoma.
TLDR
Although Burkitt lymphoma cells are extremely chemosensitive, biologically targeted therapies should be developed because current treatment options are suboptimal for patients with poor prognostic features or in the setting of relapsed disease.
c‐Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome
TLDR
Findings show that c‐Flip could be a reliable prognostic factor in Burkitt's lymphoma/leukaemia, suggesting new therapeutic approaches that target the NF‐κB pathway.
Graft versus Burkitt's Lymphoma Effect after Allogeneic Marrow Transplantation
TLDR
A patient with t(8;22) Burkitt's lymphoma who underwent an HLA-identical sibling allograft in second complete remission is reported, suggesting that immunotherapeutic approaches should be considered for Burkitts lymphoma unable to be cured by conventional chemotherapy.
Novel Treatment of Burkitt Lymphoma with Dose-Adjusted EPOCH-Rituximab: Preliminary Results Showing Excellent Outcome.
TLDR
DA-EPOCH-R appears to be highly effective with relatively low toxicity compared to standard intensive high-dose regimens for BL and may reduce or eliminate the risk of tumor lysis syndrome.
Clinical, Immunophenotypic, and Genetic Analysis of Adult Lymphomas With Morphologic Features of Burkitt Lymphoma
TLDR
The data suggest that only a few cases of these gray zone lymphomas represent true de novo BL, and immunohistochemistry for Ki-67, CD10, and bcl2 with analysis of MYC and preferably also BCL2 and BCL6 may be advised as a marker panel for this diagnostic dilemma.
Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types).
TLDR
By using aggressive multiagent therapy, cure can be expected in a high percentage of adults with small noncleaved cell lymphoma and in the subset with adverse prognostic features, more effective therapy is necessary.
Modified Magrath Regimens for Adults with Burkitt and Burkitt-Like Lymphomas: Preserved Efficacy with Decreased Toxicity
TLDR
This modified Magrath regimen is effective and well-tolerated in a representative group of older adult patients and was associated with no grade 3/4 neuropathy and only one episode of grade 3-4 mucositis.
...
1
2
3
4
5
...